Among patients with non-Hodgkin's lymphoma that were given a high dose of the drug, only 10% saw their cancer shrink - a response rate far lower than expected.
Tuesday, August 18, 2009
Genmab - Arzerra: clinical trials, ain't they a bitch!
A clinical trial of Arzerra, a drug being developed by Danish biotechnology company Genmab and backed by Glaxo, had proven disappointing, Genmab management said yesterday.
Among patients with non-Hodgkin's lymphoma that were given a high dose of the drug, only 10% saw their cancer shrink - a response rate far lower than expected.
Among patients with non-Hodgkin's lymphoma that were given a high dose of the drug, only 10% saw their cancer shrink - a response rate far lower than expected.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment